Metabolic dysfunction-associated steatohepatitis, better known as MASH, is a progressive liver disease driven largely by metabolic problems such as insulin resistance, obesity, abnormal cholesterol levels, and type 2 diabetes. It often develops quietly, causing little more than fatigueor no noticeable symptoms at allwhile inflammation and scar tissue gradually build inside the liver.
That silence is what makes MASH tricky. Your liver rarely sends an angry text message saying, “We need to talk.” Instead, the condition may first appear as elevated liver enzymes during a routine physical, fatty changes on an ultrasound ordered for another reason, or abnormal results from a fibrosis assessment.
Early detection matters because MASH can sometimes improve with sustained lifestyle changes and appropriate medical treatment. Left unmanaged, however, it may progress to advanced fibrosis, cirrhosis, liver failure, or liver cancer. MASH is also closely connected with cardiovascular disease, diabetes, and other metabolic complications, so protecting the liver usually means improving the health of the entire body.
What Is Metabolic Dysfunction-Associated Steatohepatitis?
MASH is the inflammatory and potentially progressive form of metabolic dysfunction-associated steatotic liver disease, or MASLD. These terms replaced the older names nonalcoholic steatohepatitis, or NASH, and nonalcoholic fatty liver disease, or NAFLD.
In simple MASLD, excess fat accumulates in liver cells, but there may be little inflammation or cellular injury. In MASH, the liver contains excess fat plus inflammation and damaged liver cells. As the organ repeatedly tries to repair that damage, scar tissue called fibrosis can form.
Fibrosis is commonly described in stages:
- F0: No fibrosis.
- F1: Mild fibrosis.
- F2: Moderate fibrosis.
- F3: Advanced fibrosis.
- F4: Cirrhosis, meaning extensive and potentially irreversible scarring.
Not everyone with MASLD develops MASH, and not everyone with MASH develops cirrhosis. Progression varies considerably among individuals. Type 2 diabetes, multiple metabolic risk factors, increasing age, genetic susceptibility, and more advanced fibrosis can raise the likelihood of serious liver-related complications.
How Common Is MASH?
MASH is no longer considered an unusual liver problem. The FDA estimated in 2025 that approximately 6% of U.S. adultsabout 14.9 million peoplehad MASH. The condition is particularly common among people with type 2 diabetes, obesity, high triglycerides, or other features of metabolic syndrome.
The connection with diabetes is especially strong. According to the American Diabetes Association, MASLD affects about 70% of people with type 2 diabetes in the United States, and a substantial portion of those individuals may have the more progressive MASH form. That is why liver health is increasingly becoming part of comprehensive diabetes care rather than a completely separate conversation.
Symptoms of MASH
Early MASH May Cause No Symptoms
MASH is frequently described as a silent disease. A person may have liver fat, active inflammation, and even fibrosis without feeling obviously ill. Normal energy levels do not guarantee a normal liver, and mildly elevated liver enzymes may be the only early clue.
When symptoms do occur, they may include:
- Persistent tiredness or low energy
- Weakness
- A dull ache or discomfort in the upper-right abdomen
- Reduced appetite
- Difficulty concentrating or a general sense of feeling unwell
These complaints are not unique to MASH. Fatigue, for example, can come from poor sleep, anemia, thyroid disease, depression, infections, and roughly a thousand other things the human body enjoys using to keep doctors humble. Symptoms alone therefore cannot confirm the diagnosis.
Symptoms of Advanced Liver Damage
As fibrosis progresses toward cirrhosis, more serious warning signs may appear:
- Yellow skin or eyes, known as jaundice
- Swelling in the legs or ankles
- Fluid accumulation in the abdomen, called ascites
- Unexplained weight loss or muscle loss
- Easy bruising or bleeding
- Dark urine or unusually pale stools
- Itchy skin
- Confusion, unusual sleepiness, personality changes, or slurred speech
- Vomiting blood or passing black, tarry stools
Confusion can result from hepatic encephalopathy, while vomiting blood or black stools may indicate bleeding from enlarged veins in the digestive tract. These symptoms require urgent medical evaluation.
What Causes MASH?
MASH does not have one single cause. It usually develops through an interaction between metabolic dysfunction, genetics, diet, fat distribution, inflammation, and environmental factors.
Insulin Resistance
Insulin resistance is one of the central drivers. When muscle, fat, and liver cells stop responding normally to insulin, the body may produce more of the hormone to keep blood sugar controlled. This encourages the release and storage of fatty acids, including fat inside the liver.
Excess liver fat can interfere further with insulin signaling, creating an unpleasant metabolic loop: insulin resistance encourages liver fat, and liver fat worsens insulin resistance. The liver is essentially trapped in a group project where nobody is communicating.
Lipotoxicity and Inflammation
Not all stored fat is equally harmless. Certain fatty acids and lipid byproducts can stress liver cells, damage mitochondria, increase oxidative stress, and activate inflammatory pathways. Injured cells then release signals that recruit immune cells and activate scar-producing cells.
Over time, repeated injury and repair may replace healthy tissue with fibrosis. Researchers are also investigating the roles of gut bacteria, intestinal permeability, bile acids, hormones, and immune-system signaling in determining why some people remain at simple steatosis while others develop MASH.
Genetics and Family History
Genetic differences can influence how the liver stores fat and responds to injury. Variants in genes such as PNPLA3 are associated with greater susceptibility to steatotic liver disease and fibrosis. This helps explain why MASH can occur in people who do not appear severely overweight and why two individuals with similar lifestyles may have very different liver outcomes.
Major MASH Risk Factors
A person is more likely to develop MASLD or MASH when one or more of the following are present:
- Overweight or obesity, especially excess abdominal fat
- Type 2 diabetes or prediabetes
- Insulin resistance
- High triglycerides
- High LDL cholesterol or low HDL cholesterol
- High blood pressure
- Metabolic syndrome
- Obstructive sleep apnea
- Polycystic ovary syndrome
- A family history of metabolic or liver disease
- A sedentary lifestyle
- A diet high in added sugars, refined carbohydrates, and heavily processed foods
Alcohol may contribute additional liver injury, even when metabolic dysfunction is the primary driver. Doctors therefore ask about alcohol intake when evaluating fatty liver because MASLD, alcohol-associated liver disease, and mixed forms of steatotic liver disease can overlap.
How MASH Is Diagnosed
Medical History and Physical Examination
The diagnostic process usually starts with a review of weight history, medications, supplements, alcohol use, diabetes, cholesterol, blood pressure, sleep apnea, family history, and previous laboratory results.
A clinician may check for abdominal obesity, an enlarged liver, darkened skin patches associated with insulin resistance, muscle loss, abdominal fluid, or other signs of advanced liver disease. A normal physical examination does not rule out MASH.
Blood Tests
Common tests include ALT, AST, bilirubin, albumin, alkaline phosphatase, platelet count, blood sugar, A1C, cholesterol, and triglycerides. Additional testing may be used to exclude viral hepatitis, autoimmune liver disease, iron overload, medication-related injury, and other possible explanations.
ALT and AST can be normal in someone with significant fibrosis, so liver enzymes should not be treated as a perfect report card. Doctors often combine routine results into risk scores such as the FIB-4 index, which uses age, AST, ALT, and platelet count to estimate the likelihood of advanced fibrosis.
Imaging and Elastography
An abdominal ultrasound can detect liver fat, although it may miss mild steatosis and cannot reliably determine whether inflammation is present. CT and MRI scans can provide additional information about liver structure and fat.
Elastography measures liver stiffness as a marker of fibrosis. Options include vibration-controlled transient elastography, commonly known by the brand name FibroScan, shear-wave elastography, and magnetic resonance elastography. These tests are noninvasive and increasingly useful for deciding who needs specialist care or additional evaluation.
Liver Biopsy
A liver biopsy remains the clearest method for confirming steatohepatitis and directly assessing inflammation, liver-cell injury, and fibrosis. However, it is not necessary for every patient. Because biopsy is invasive and can be affected by sampling variation, clinicians often begin with blood-based scores and elastography.
A biopsy may be considered when noninvasive tests disagree, the diagnosis remains uncertain, another liver condition is suspected, or the result would affect treatment decisions.
Treatment for MASH
MASH treatment is based on two connected goals: reducing liver inflammation and fibrosis while improving the metabolic conditions that caused the damage. A prescription alone cannot replace nutrition, physical activity, sleep, diabetes care, blood-pressure control, and long-term follow-up.
Gradual, Sustainable Weight Loss
For people with excess weight, losing approximately 3% to 5% of starting body weight may reduce liver fat. Greater lossesoften around 7% to 10% or moremay be needed to meaningfully reduce inflammation and fibrosis.
Weight loss should be gradual and sustainable. Crash diets can produce nutrient deficiencies, muscle loss, rapid weight regain, and in some circumstances worsening liver problems. A smaller change that survives birthdays, vacations, deadlines, and Tuesday-night pizza temptation is more valuable than a dramatic two-week transformation.
A Liver-Friendly Eating Pattern
No single food causes MASH, and no magical detox smoothie power-washes the liver. A practical eating pattern generally emphasizes:
- Vegetables and whole fruits
- Beans, lentils, and other high-fiber foods
- Whole grains
- Fish, poultry, tofu, and other minimally processed proteins
- Nuts, seeds, olive oil, and other unsaturated fats
- Reasonable portion sizes
A Mediterranean-style diet is frequently recommended because it supports weight management and cardiovascular health. Sugary drinks, excessive added sugar, refined carbohydrates, heavily processed snacks, and frequent oversized portions should be reduced. Water is considerably less exciting than a giant soda, but the liver appreciates its lack of high-fructose drama.
Regular Physical Activity
Exercise can reduce liver fat and improve insulin sensitivity even when the scale barely moves. Many adults work toward at least 150 minutes of moderate-intensity aerobic activity per week, combined with strength training when medically appropriate.
The best program is one that is safe enough to start and enjoyable enough to repeat. Brisk walking, cycling, swimming, resistance exercises, dancing, and active household work can all contribute. People who have been inactive or who have heart, joint, or advanced liver problems should ask a healthcare professional how to begin safely.
Managing Diabetes, Cholesterol, and Blood Pressure
MASH care should include aggressive management of type 2 diabetes, triglycerides, cholesterol, high blood pressure, sleep apnea, and cardiovascular risk. Depending on the person, the care team may include a primary care clinician, hepatologist, gastroenterologist, endocrinologist, cardiologist, registered dietitian, obesity-medicine specialist, and exercise professional.
FDA-Approved Medicines for MASH
As of August 2026, two medications are FDA-approved for certain adults with noncirrhotic MASH and moderate-to-advanced fibrosis:
- Resmetirom, sold as Rezdiffra: Approved in March 2024 for adults with noncirrhotic MASH and F2-F3 fibrosis, in combination with diet and exercise. It activates a thyroid hormone receptor in the liver, helping reduce liver fat. Common adverse effects include diarrhea and nausea, and the prescribing information includes warnings concerning liver toxicity, gallbladder problems, and drug interactions.
- Semaglutide, sold as Wegovy: Approved for MASH in August 2025 under the accelerated approval pathway for adults with moderate-to-advanced fibrosis. It is used with a reduced-calorie diet and increased physical activity. Common adverse effects are primarily gastrointestinal, including nausea, vomiting, diarrhea, constipation, and abdominal discomfort.
Neither drug is a universal cure. Selection depends on fibrosis stage, cirrhosis status, weight, diabetes, cardiovascular risk, medication interactions, contraindications, side-effect tolerance, insurance coverage, and patient preference. Both approvals were based on liver-biopsy improvements, with longer-term studies continuing to confirm effects on outcomes such as liver failure, transplantation, and survival.
Bariatric Surgery
Metabolic or bariatric surgery may be considered for selected people with obesity who meet surgical criteria. Significant and sustained weight loss can improve MASLD and may resolve MASH before cirrhosis develops. Surgery is not appropriate for everyone, and advanced liver disease requires careful evaluation by specialists experienced in both bariatric and liver care.
Treatment of Cirrhosis
When MASH has progressed to cirrhosis, treatment shifts toward preventing and managing complications. Patients may need screening for liver cancer, evaluation for enlarged esophageal veins, treatment for fluid retention, management of hepatic encephalopathy, and regular monitoring of liver function.
People with decompensated cirrhosis or liver failure may need evaluation for a liver transplant. This is one reason fibrosis stage matters so much: the amount of scarring often predicts future risk more strongly than the amount of fat alone.
Can MASH Be Prevented?
Not every case is preventable, especially when genetic susceptibility or unavoidable medical factors are involved. However, the risk can often be lowered by improving metabolic health before substantial liver injury develops.
- Maintain a healthy weight or pursue gradual weight loss when appropriate.
- Exercise regularly and reduce long periods of sitting.
- Limit sugary beverages, refined carbohydrates, and heavily processed foods.
- Manage blood sugar, cholesterol, triglycerides, and blood pressure.
- Get evaluated for sleep apnea when symptoms suggest it.
- Discuss alcohol use honestly with a healthcare professional.
- Avoid smoking and tobacco products.
- Review medications, vitamins, and herbal supplements with a clinician.
- Ask whether hepatitis A and B vaccination is appropriate.
People with type 2 diabetes, obesity, several metabolic risk factors, persistently abnormal liver tests, or liver fat found on imaging should discuss fibrosis assessment with a healthcare professional. Waiting for symptoms is unreliable because the liver can remain remarkably quiet while damage accumulates.
When Should You See a Doctor?
Schedule an appointment if routine testing shows elevated liver enzymes, an ultrasound identifies liver fat, or you have diabetes, obesity, metabolic syndrome, or several cardiovascular risk factors. Ask whether you need a FIB-4 calculation, elastography, or referral to a liver specialist.
Seek urgent care for yellow skin or eyes, rapidly increasing abdominal swelling, vomiting blood, black stools, severe confusion, fainting, unusual drowsiness, or sudden worsening weakness. These may indicate advanced liver dysfunction or internal bleeding.
Conclusion
MASH is a serious but increasingly treatable metabolic liver disease. It begins with excess liver fat and progresses when inflammation, liver-cell injury, and fibrosis join the party uninvited. Because the condition may remain symptom-free for years, early risk assessment is essentialparticularly for people with type 2 diabetes, obesity, abnormal cholesterol, high blood pressure, or metabolic syndrome.
Effective management is rarely built around a single heroic intervention. Sustainable weight loss, regular movement, improved nutrition, control of diabetes and cardiovascular risk, appropriate fibrosis monitoring, and carefully selected medication can work together to protect the liver. Modern treatments such as resmetirom and semaglutide have expanded the medical toolbox, but lifestyle care and long-term follow-up remain the foundation.
Experiences Related to Living With MASH
The following section presents fictionalized composite experiences based on common challenges reported by people undergoing evaluation and treatment for metabolic liver disease. It does not describe one identifiable patient.
The Unexpected Diagnosis
A common MASH experience begins with surprise rather than symptoms. Imagine a 52-year-old office manager named Daniel. He schedules a routine physical expecting the usual conversation about cholesterol and perhaps a reminder that cookies are not technically a vegetable. His blood work shows mildly elevated ALT and AST levels.
Daniel feels fine, so the result seems unimportant. His clinician, however, notices that he also has type 2 diabetes, high triglycerides, high blood pressure, and excess abdominal weight. An ultrasound shows liver fat, while a FIB-4 calculation and FibroScan suggest meaningful fibrosis. Further evaluation confirms MASH.
The diagnosis feels confusing because Daniel rarely drinks alcohol. Learning that the disease is driven mainly by metabolic dysfunction helps replace shame with a practical plan. His liver problem is connected with the same insulin resistance affecting his blood sugar, blood pressure, and cholesterol.
Changing Food Without Declaring War on Dinner
Daniel initially assumes he must live on plain lettuce and sadness. A registered dietitian offers a less theatrical strategy. Instead of banning every favorite food, they focus on repeatable changes: water instead of sugary soda during the workweek, vegetables with lunch and dinner, smaller restaurant portions, fewer late-night snacks, and more meals built around beans, fish, chicken, whole grains, and olive oil.
Progress is imperfect. There are holidays, business lunches, and one memorable weekend involving barbecue. Rather than treating those moments as failure, Daniel returns to his usual routine at the next meal. Over several months, he loses weight gradually and notices that his blood sugar readings become easier to manage.
Discovering That Exercise Does Not Require Lycra
Another common obstacle is the belief that exercise must involve a gym membership, expensive equipment, and the ability to look cheerful while doing burpees. Daniel begins with a 10-minute walk after dinner. As his endurance improves, he reaches 30 minutes on most days and adds two short strength-training sessions each week.
The scale occasionally refuses to cooperate, but his waist measurement shrinks, energy improves, and repeat metabolic tests move in the right direction. This is an important experience for many people with MASH: exercise can benefit liver fat, blood sugar, cardiovascular fitness, and muscle health even when weight loss is slower than expected.
Medication Decisions and Follow-Up
Because Daniel has F2 fibrosis, his hepatologist discusses available MASH medications. The conversation includes expected benefits, possible side effects, existing diabetes treatment, cholesterol medicine, insurance coverage, and the reality that medication works best alongside lifestyle changes.
Follow-up visits involve more than checking liver enzymes. His team monitors weight, A1C, lipids, blood pressure, symptoms, medication tolerance, and fibrosis markers. Daniel learns that a normal ALT result is encouraging but does not automatically prove that all scar tissue has disappeared.
The Emotional Side of MASH
People with MASH may feel guilt, fear, frustration, or embarrassment. Some believe they caused the disease through personal failure. Others become anxious about cirrhosis after reading worst-case stories online at 2 a.m., a time when the internet is famously calm and reassuring.
Supportive care reframes the condition as a complex chronic disease influenced by biology, environment, genetics, medications, sleep, stress, food access, and metabolic health. Personal habits matter, but blame is neither scientifically accurate nor medically useful.
After a year, Daniel has not achieved a movie-montage transformation. He has achieved something more valuable: steady weight loss, improved diabetes control, consistent activity, better food habits, and no evidence that his fibrosis is worsening. His experience reflects the real rhythm of MASH caresmall decisions, repeated often, with regular medical guidance and the occasional stubborn Tuesday.
Medical note: This article provides general educational information and is not a substitute for diagnosis or individualized treatment. People with suspected MASH, abnormal liver tests, or signs of advanced liver disease should consult a qualified healthcare professional. Do not begin medications, vitamins, herbal products, extreme diets, or weight-loss programs without appropriate medical guidance.
